Little Spark Yet For Xelpros Amid New CRL
This article was originally published in Scrip
Executive Summary
Sun Pharma Advanced Research Company (SPARC) has received a second complete response letter (CRL) from the FDA to its new drug application (NDA) for Xelpros (latanoprost BAK-free eyedrops), though the company claims this concerns "minor" labelling modifications.
You may also be interested in...
Xelpros Approval Adds Spark To Sun’s Site Too?
Xelpros may not be seen as a huge money-spinner, but its approval by the US FDA signals Sun Pharma's expanding interest in the US ophthalmology space. The clearance also potentially indicates that recent compliance issues at the company’s Halol site may not be all-encompassing.
Sun’s Halol Site Out Of Compliance Rut, Could Add Some SPARC Too
Sun's Halol manufacturing facility is over the compliance hump, receiving an EIR [Establishment Inspection Report] from the US FDA. The site, seen as core to India's top ranked firm's promising filings, including injectables, is also expected to lift the prospects of Sun's spin-off R&D arm, SPARC.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.